Janus Capital Management LLC Has $905.01 Million Position in Allergan PLC. (AGN)
Janus Capital Management LLC decreased its position in shares of Allergan PLC. (NYSE:AGN) by 2.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,787,948 shares of the company’s stock after selling 109,925 shares during the period. Allergan PLC. comprises about 0.7% of Janus Capital Management LLC’s portfolio, making the stock its 16th largest position. Janus Capital Management LLC owned approximately 1.13% of Allergan PLC. worth $905,009,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Manning & Napier Advisors LLC boosted its position in Allergan PLC. by 21.3% in the first quarter. Manning & Napier Advisors LLC now owns 11,980 shares of the company’s stock worth $2,862,000 after buying an additional 2,100 shares during the last quarter. Trust Co boosted its position in Allergan PLC. by 0.7% in the fourth quarter. Trust Co now owns 1,214 shares of the company’s stock worth $255,000 after buying an additional 9 shares during the last quarter. Raymond James Trust N.A. boosted its position in Allergan PLC. by 7.6% in the first quarter. Raymond James Trust N.A. now owns 8,868 shares of the company’s stock worth $2,119,000 after buying an additional 629 shares during the last quarter. Charter Trust Co. bought a new position in Allergan PLC. during the first quarter worth $213,000. Finally, Douglass Winthrop Advisors LLC boosted its position in Allergan PLC. by 15.6% in the first quarter. Douglass Winthrop Advisors LLC now owns 11,675 shares of the company’s stock worth $2,789,000 after buying an additional 1,574 shares during the last quarter. 84.77% of the stock is currently owned by hedge funds and other institutional investors.
Allergan PLC. (NYSE AGN) traded down 0.15% during trading on Monday, hitting $242.28. The stock had a trading volume of 543,605 shares. The company has a market cap of $81.37 billion, a PE ratio of 7.55 and a beta of 1.16. The company’s 50 day moving average is $245.21 and its 200-day moving average is $237.12. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter last year, the business posted $3.35 earnings per share. The firm’s revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts predict that Allergan PLC. will post $16.20 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.15%. Allergan PLC.’s payout ratio is 9.95%.
A number of research analysts recently commented on AGN shares. Royal Bank Of Canada set a $279.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Wednesday, April 12th. Citigroup Inc. reissued a “focus list” rating and issued a $261.27 price target (up from $184.50) on shares of Allergan PLC. in a report on Friday, April 21st. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a report on Wednesday, May 10th. UBS AG reissued a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Seven analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Allergan PLC. currently has a consensus rating of “Buy” and an average target price of $274.14.
In related news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.